AIBotics, Inc. is a biotech and technology firm integrating AI and robotics to develop products aimed at mental health treatment and wellness, particularly leveraging psychedelics like psilocybin, with a focus on research, development, and potential future commercialization within a rapidly evolving legal and regulatory landscape.

# Company Summary: AIBotics, Inc.

## Business Overview
- **Core Focus:** Promotes the study of psychedelics for mental health treatment, supporting the development of natural and synthetic molecules for therapeutic purposes.
- **Research & Clinical Data:** Supports collection and analysis of research and clinical data related to the effects of psychedelics in mental health treatments, leveraging technology from its parent company, Ehave, Inc.
- **Artificial Intelligence & Robotics:** Uses AI in robotics to enhance quality of life, particularly after acquiring assets from Philon Labs, including AI-powered products like the Phill Robot (massage robot) and MilkyWay (smart breast milk storage refrigerator).
- **Product Offerings:**
  - **Phill Robot:** AI-powered massage robot that learns user preferences for personalized massage experiences; features a foldable design serving as a nightstand.
  - **MilkyWay:** Smart milk storage refrigerator with automated vertical rotating system, customizable capacity (up to 99 or 120+ bags), and a mobile app for real-time monitoring.
- **Supply Agreements:** Has ongoing supply agreements with Havn Life Sciences Inc. for natural psilocybin derivatives, to support research and develop psychedelic-based therapies.
- **Acquisition & Asset Development:** Acquired assets from Philon Labs including patents and intellectual property related to AI robotics, shifting focus towards innovative products in wellness and healthcare.

## Market & Industry
- Opportunity driven by legal advancements: Oregon became the first U.S. state to legalize psilocybin in 2020.
- Market Growth: Psychedelic drugs market expected to grow at 12.4% annually, reaching $10.75 billion by 2027.
- Regulatory landscape: Recognized FDA breakthrough therapy designations for psychedelics such as MDMA and psilocybin, positioning the company within a rapidly evolving regulatory framework for mental health therapies.

## Company Structure & Strategy
- **Incorporation & Subsidiaries:** Incorporated in Nevada in 2000; wholly owned subsidiary AIBotics Therapies Inc. in Florida.
- **Partnerships & Contracts:** Has supply agreements and strategic relationships for developing psilocybin-based products.
- **Research & Development:** Focused on integrating AI and robotics to develop disruptive wellness products, with an emphasis on mental health applications using psychedelics.
- **Operational Status:** Virtually operated, with no physical properties owned.

## Financial & Operational Data
- **Employees & Customers:** No specific information provided.
- **Revenue:** No revenue was reported for fiscal years 2024 and 2023.
- **Net Income:** 
  - 2024: Loss of $1,848,275
  - 2023: Loss of $1,181,347
- **Shares Outstanding:** 42,690,903 as of March 31, 2025.
- **Market Capitalization:** Approximate market value held by non-affiliates was $1,373,539 as of June 30, 2024.
- **Financial Status:** Continues to operate at a net loss with significant working capital deficiency ($4,666,666 deficit as of December 31, 2024), and dependence on future financing to sustain operations.

## Summary
AIBotics, Inc. is a biotech and technology firm integrating AI and robotics to develop products aimed at mental health treatment and wellness, particularly leveraging psychedelics like psilocybin, with a focus on research, development, and potential future commercialization within a rapidly evolving legal and regulatory landscape. The company has not yet generated revenue and operates at a significant net loss, relying on ongoing capital raises.

Mycotopia Therapies, Inc. focuses on the research and development of psychedelic treatments for mental health issues, particularly using psilocybin.

# Mycotopia Therapies, Inc. Overview

## Business Focus
Mycotopia Therapies, Inc. is focused on the study and application of psychedelics for mental health treatment. The company promotes research and development of both natural and synthetic psychedelic compounds, particularly psilocybin, seeking to address issues like depression, addiction, and chronic pain.

## Key Initiatives
1. **Psychedelic Research and Therapies:**
   - The company collaborates with institutions to facilitate studies aimed at validating the efficacy of psychedelics for mental health issues.
   - Holds a supply agreement with Havn Life Sciences for naturally derived psilocybin used in clinical research.

2. **Integration of Technology:**
   - Utilizes technology from its parent company, Ehave, Inc., for data collection and analysis in research.
   - Engages in neuroscience through partnerships involving EEG brain cap technology.

3. **Recent Acquisitions:**
   - Acquired assets from Philon Labs, including the “Phill Robot” and “Milky Way” products, signifying a shift towards AI and robotics to improve wellness and quality of life.

## Notable Products
- **Phill Robot:** An AI-powered massage robot designed to provide personalized at-home massage experiences.
- **Milky Way:** A specialized smart refrigerator for breast milk, featuring a patent-pending storage system that aids in inventory management for parents and healthcare providers.

## Market Opportunity
- **Psychedelic Market Growth:** Estimated at 12.4% annual growth, potentially reaching $10.75 billion by 2027.
- **Legal Landscape Evolution:** Increasing legal acceptance of psychedelics for therapeutic uses, notably in states like Oregon.

## Financial Overview (as of the latest report)
- **Number of Employees:** Not specifically stated in the summary.
- **Revenue and Income:** Detailed revenue and income figures are not provided in the presented information.
- **Share Trading Symbol:** TPIA

## Governance and Compliance
- Mycotopia Therapies is committed to adhering to regulatory compliance for research and development involving psychedelics, under FDA guidelines and federal regulations relating to controlled substances.

## Future Direction
- The company plans to focus on establishing a strong market presence in psychedelics, developing a pipeline of pharmaceutical-grade components for treatments, and enhancing its product offerings through continued technological and therapeutic innovations. 

## Cybersecurity and Data Protection
- Implements robust cybersecurity protocols to protect its digital assets and intellectual property, including employee training, multifactor authentication, and regular security assessments.

---

This summary encapsulates the essential details about Mycotopia Therapies, Inc. while acknowledging that specific figures related to customers, employees, revenue, and income are either not directly available or stated in the provided business overview.

AIBOTICS, INC.

10-K / April 11, 2025

10-K / April 23, 2024

10-K / April 11, 2025

Company Summary: AIBotics, Inc.

Business Overview

Market & Industry

Company Structure & Strategy

Financial & Operational Data

Summary